Eisler Capital Management Ltd. Makes New Investment in Amedisys, Inc. (NASDAQ:AMED)

Eisler Capital Management Ltd. purchased a new position in Amedisys, Inc. (NASDAQ:AMED) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 40,000 shares of the health services provider’s stock, valued at approximately $3,631,000. Eisler Capital Management Ltd. owned about 0.12% of Amedisys at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. Blue Trust Inc. lifted its holdings in Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after purchasing an additional 124 shares during the last quarter. HBW Advisory Services LLC bought a new position in shares of Amedisys in the fourth quarter valued at approximately $38,000. Johnson Financial Group Inc. acquired a new stake in shares of Amedisys in the fourth quarter worth $55,000. Vestcor Inc bought a new stake in shares of Amedisys during the 4th quarter worth $73,000. Finally, Venturi Wealth Management LLC grew its stake in Amedisys by 397.4% in the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock valued at $89,000 after buying an additional 779 shares during the last quarter. Institutional investors own 94.36% of the company’s stock.

Amedisys Trading Down 0.9 %

Shares of AMED opened at $95.24 on Friday. The stock’s 50-day moving average price is $92.91 and its 200 day moving average price is $91.74. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $3.13 billion, a price-to-earnings ratio of 37.79, a P/E/G ratio of 1.78 and a beta of 0.96. Amedisys, Inc. has a 12-month low of $82.15 and a 12-month high of $98.95.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.12. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business had revenue of $594.78 million during the quarter, compared to analyst estimates of $597.43 million. During the same period in the prior year, the company posted $1.03 earnings per share. Amedisys’s revenue was up 4.1% on a year-over-year basis. As a group, research analysts predict that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on AMED. Royal Bank of Canada restated an “outperform” rating and set a $100.00 price target on shares of Amedisys in a report on Wednesday, April 16th. Stephens restated an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a research note on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, Amedisys presently has a consensus rating of “Hold” and a consensus target price of $100.75.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.